Abiopharma

🔍 O'NEIL PATRICK R. (Executive)

Company: IONIS PHARMACEUTICALS INC (IONS)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 13,050 shares of Common Stock at $32.6 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 70,180.00 | transaction_form_type: 4
• Sold 13,050 shares of Common Stock at $54.5148 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 57,130.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 14,000 shares of Common Stock at $37.58 per share (Direct)
  Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 71,130.00 | transaction_form_type: 4
• Sold 65,475 shares of Common Stock at $60.89 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,655.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Acquired 13,050 shares of Common Stock at $32.6 per share (Direct)
  Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,705.00 | transaction_form_type: 4
• Sold 11,375 shares of Common Stock at $61.42 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,330.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Acquired 49,800 shares of Common Stock at $53.77 per share (Direct)
  Date: 2025-09-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 57,130.00 | transaction_form_type: 4
• Sold 13,050 shares of Non-Qualified Stock Option (right to buy) at $32.6 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2032-01-02 | Exercise: 2023-01-03 | equity_swap_involved: 0 | shares_owned_after: 17,517.00 | transaction_form_type: 4
• Sold 13,050 shares of Non-Qualified Stock Option (right to buy) at $32.6 per share (Derivative)
  Date: 2025-09-03 | Code: M | Expires: 2032-01-02 | Exercise: 2023-01-03 | equity_swap_involved: 0 | shares_owned_after: 4,467.00 | transaction_form_type: 4
• Sold 14,000 shares of Non-Qualified Stock Option (right to buy) at $37.58 per share (Derivative)
  Date: 2025-09-03 | Code: M | Expires: 2033-01-02 | Exercise: 2024-01-03 | equity_swap_involved: 0 | shares_owned_after: 8,942.00 | transaction_form_type: 4
• Sold 49,800 shares of Non-Qualified Stock Option (right to buy) at $53.77 per share (Derivative)
  Date: 2025-09-03 | Code: M | Expires: 2026-01-01 | Exercise: 2020-01-02 | equity_swap_involved: 0 | transaction_form_type: 4

Footnotes:

• F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025.
• F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to 54.59, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
• F3: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.3418 to $61.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.35 to $61.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5)on this Form 4.